OPTION CARE

The question every serious healthcare franchise investor faces is this: am I looking at the ground floor of a transformative healthcare delivery model, or am I examining the remnant of a franchise system that has long since been absorbed into a massive corporate structure? That tension sits at the heart of any rigorous analysis of the OPTION CARE franchise opportunity, and resolving it requires understanding one of the most remarkable corporate evolution stories in American healthcare. OPTION CARE traces its origins to 1979, when two California pharmacists, Michael Prime and Mitchell Hoggard, recognized a profound gap in healthcare delivery while working in Chico, California. The initial inspiration came from a young patient who required daily intravenous nutrition and had no viable alternative to prolonged, expensive hospitalization. What Prime and Hoggard built — first called CliniCare, then formalized as a legal partnership in 1980, and eventually renamed O.P.T.I.O.N. Care in 1983, an acronym for Outpatient Parenteral Therapy and Intravenous Ongoing Nutrition — addressed a structural failure in American healthcare that remains relevant today. The franchise model they developed was genuinely pioneering: during the period from 1984 to 1990, OPTION CARE was documented as the only firm with a franchise concept in its competitive landscape, building a network that by the early 2000s comprised 130 pharmacies, including 27 company-owned locations and 103 franchised units. Today, the parent corporation, Option Care Health, Inc., is headquartered in Bannockburn, Illinois, operates across all 50 states, and generated $5.65 billion in net revenue for full year 2025. The franchise database entry currently reflects 4 total units, all franchised, with an initial investment range of $100,000 to $208,000, representing what appears to be a distinct, smaller-scale franchise entity operating under the broader OPTION CARE brand heritage rather than the large corporate parent. The total addressable market for home infusion services in the United States was valued at $18.82 billion in 2023 and is projected to reach $33.2 billion by 2030, a compound annual growth rate of 8.4%. For franchise investors evaluating home health care services, understanding the full historical and structural context of the OPTION CARE brand is not optional — it is the entire analytical exercise.

The home infusion and home health care services industry sits at the intersection of two of the most powerful secular trends reshaping American medicine. First, the persistent and accelerating demand to move complex medical treatments out of high-cost hospital settings and into patients' homes, driven by cost pressures that affect payers, providers, and patients simultaneously. Second, the rapid proliferation of specialty medicines, including biologics, oncology treatments, and rare disease therapies, that require skilled administration but not necessarily inpatient infrastructure. The U.S. home infusion market, valued at $18.82 billion in 2023, is forecast to reach approximately $20.59 billion by 2033 using a conservative 8.05% CAGR estimate, with more aggressive projections placing the 2030 figure at $33.2 billion. These two estimates reflect different methodological assumptions, but both confirm a sustained, multi-decade expansion trajectory that makes home health care services one of the most defensible categories in franchise investment. Consumer preference data reinforces the structural case: patients across all demographic cohorts increasingly prefer receiving care at home, driven by comfort, convenience, and growing awareness of hospital-acquired infection risks. The aging of the U.S. population creates an expanding base of chronic disease patients who require ongoing infusion therapies — precisely the patient profile that generates the highest per-patient revenue and the most predictable recurring demand. Digital health integration, including real-time data sharing platforms and remote care management tools, is further enabling clinical-grade care delivery outside hospital walls. The competitive landscape for home infusion services has historically been fragmented, which created the original opening for a franchise model in the 1980s, but consolidation has been rapid and substantial since 2010. The OPTION CARE franchise opportunity, with its 4-unit current footprint and $100,000 to $208,000 investment range, sits in a dramatically different competitive tier than the multi-billion-dollar national operators, which creates both risk considerations and potential niche positioning advantages that investors must carefully evaluate.

The OPTION CARE franchise investment range of $100,000 to $208,000 positions this opportunity in the accessible-to-mid-tier band of healthcare franchise investments, a meaningful structural characteristic when evaluating entry economics against the category context. The spread between the $100,000 floor and the $208,000 ceiling — a $108,000 range — typically reflects variables including geographic build-out costs, facility lease requirements, initial inventory and pharmacy licensing requirements, equipment procurement, and working capital reserves necessary to sustain operations through the ramp-up period before patient volume reaches breakeven thresholds. Home health care service businesses, and infusion pharmacy models specifically, carry regulatory and licensing overhead that general retail franchises do not face, including state pharmacy board requirements, accreditation costs, controlled substance registrations, and payer credentialing timelines that can extend six to twelve months post-opening before full revenue-generating capacity is achieved. This means the effective capital requirement during the initial operating phase can meaningfully exceed the stated investment range, and prospective franchisees should model working capital needs conservatively. A historical data point from OPTION CARE's franchise period indicates that $15,000 was referenced as an available capital requirement for franchisee candidates, a figure that is clearly a historical artifact given the current $100,000 to $208,000 investment range and the substantial regulatory complexity of operating any infusion-related healthcare business today. The parent corporate entity, Option Care Health, Inc., which became publicly traded in July 2019 following its merger with BioScrip, Inc., operates an entirely corporate-owned model at the national level with no current public indication of active franchising for new investors at the large-scale platform level. The 4-unit franchise network reflected in the current database entry appears to represent a distinct, smaller-scale operational structure. Prospective OPTION CARE franchise investors should verify current franchise fee structures, royalty obligations, and advertising fund contributions directly through the current Franchise Disclosure Document, as publicly available details on these specific line items are limited in recent records. The investment range of $100,000 to $208,000 compares favorably to many healthcare service franchise categories, where initial investments frequently begin above $300,000 and can exceed $1 million for pharmacy or infusion-focused models, suggesting a potentially more accessible entry point if the operational model supports the lower capital structure.

The daily operational reality of an OPTION CARE franchise centers on the delivery of home-based healthcare services, a model that is fundamentally distinct from retail or food service franchise operations and carries with it a set of staffing, regulatory, and clinical requirements that define both the opportunity and the complexity. Home infusion and home health care service businesses require licensed clinical professionals — typically registered pharmacists, registered nurses, and pharmacy technicians — as core staff rather than general labor, which means labor costs are structurally higher than most franchise categories but also means the service delivered commands correspondingly higher reimbursement rates from Medicare, Medicaid, and commercial insurance payers. The franchise training model during OPTION CARE's foundational period required that the pharmacist owner and their primary nurse complete training at the company's Chico, California headquarters prior to opening, reflecting a clinically rigorous preparation program appropriate to the service complexity. Option Care Health's current corporate training infrastructure for its employed workforce emphasizes clinical competency, with the internal nursing service, Navin Health, managing nearly 54,000 nursing visits in a single quarter in 2025, reflecting the scale of clinical operations the broader system has developed. Approximately 35% of nursing visits in Q2 2025 occurred in company-owned infusion suites, with the balance conducted in patient homes, indicating a hybrid delivery model that blends facility-based and home-visit care. Territory structure and exclusivity provisions for the current 4-unit franchise network should be evaluated through direct FDD review, as these are critical protections for any franchise investment in a service category where geographic patient access defines revenue potential. The absentee ownership model is generally challenging in clinical healthcare service businesses due to licensing requirements that often mandate an owner or designated manager to hold active professional credentials, and prospective OPTION CARE franchise investors with non-clinical backgrounds should carefully evaluate whether a qualified clinical operator or partner is part of their investment structure from day one.

Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document for the OPTION CARE franchise. This is a significant due diligence consideration. Under Federal Trade Commission franchise regulations, franchisors are not legally required to provide financial performance representations, but when they do elect to disclose, the information must appear in Item 19 of the FDD. The absence of an Item 19 disclosure means prospective investors must construct their own financial performance model using industry benchmarks, comparable unit data, and publicly available information rather than relying on franchisor-provided revenue or earnings figures. The parent corporate entity, Option Care Health, Inc., provides a useful reference framework: the company generated $4.302 billion in net revenue in 2023, $4.998 billion in 2024, and $5.65 billion in full year 2025, representing a 13% year-over-year increase. The company's gross profit margins ran at approximately 19.0% to 19.7% of net revenue across 2025 quarters, with Q1 2025 gross profit of $263.1 million on revenue of $1.333 billion. Adjusted EBITDA for full year 2025 was $471 million on $5.65 billion in revenue, producing an EBITDA margin of 8.3%. Net income for full year 2024 was $211.8 million, with Q1 through Q3 2025 net income figures of $46.7 million, $50.5 million, and $51.8 million respectively. These corporate-level financials reflect a $5 billion revenue platform with substantial infrastructure, payer relationships, and purchasing scale that a 4-unit franchise network cannot directly replicate, but they do confirm that the underlying business model in home infusion services generates real, sustained financial performance at scale. Industry revenue benchmarks for independent home infusion providers suggest unit-level annual revenues in the range of several million dollars for established locations with strong payer contracts, though the specific revenue potential of an OPTION CARE franchise unit at the current scale requires direct inquiry and independent financial modeling given the absence of Item 19 data.

The growth trajectory of Option Care Health as a corporate entity is one of the most compelling narratives in healthcare services over the past decade, even as the franchise footprint at the smaller-scale level reflected in the database entry remains modest at 4 units. The corporate parent grew its location count from 157 in Q2 2022 to 170 in Q2 2023, and by October 2025, the company's real estate operations encompassed over 200 facilities nationwide, including more than 90 pharmacies and over 750 infusion suite chairs. The 2019 merger with BioScrip, Inc., which created Option Care Health as a publicly traded entity, was the defining transformation event, establishing the combined entity as the nation's largest independent provider of home and alternate site infusion services. In 2025, Option Care Health acquired Intramed Plus, reporting that infusion clinic visits grew over 25% in Q4 2025 compared to the prior year period. The company served over 315,000 unique patients and completed more than 2.5 million infusion events in 2025, with new pharmacies and infusion suites opened in New York, Tampa, and Richmond, Virginia. Technology investment is a meaningful competitive differentiator: beginning in August 2024, Option Care Health deployed Palantir Technologies' Artificial Intelligence Platform, formalizing a multi-year partnership in January 2025, with approximately 40% of claims processed without human intervention by 2025. The company also partnered with Quince Therapeutics in August 2025 for the development of encapsulated dexamethasone sodium phosphate for Ataxia-Telangiectasia treatment, signaling expansion into rare disease therapy platforms. Revenue mix is approximately 75% chronic therapies and 25% acute therapies, with acute revenue growing in the mid-teens and chronic therapies in the low double digits during 2025. Looking forward, Option Care Health provided 2026 revenue guidance of $5.8 billion to $6.0 billion, with Adjusted EBITDA guidance of $480 million to $505 million, and cash flow from operations expected to reach at least $340 million.

The ideal OPTION CARE franchise candidate is not a general entrepreneur evaluating their first business venture but rather someone with a meaningful intersection of clinical healthcare background, business management capability, and the regulatory fluency required to navigate state pharmacy licensure, payer credentialing, and healthcare compliance frameworks. The pharmacist-owner model that characterized OPTION CARE's original franchise structure — requiring that the owner hold a pharmacy license and that their primary nurse complete headquarters training prior to opening — reflects the professional credential baseline that home infusion franchise operations demand. Multi-unit development potential exists within the home health care services category given the geographic fragmentation of the market outside major metropolitan areas, but the regulatory complexity of each new location — including individual state pharmacy board approvals, accreditation requirements, and payer network negotiations — means that the timeline from signing a franchise agreement to generating revenue is substantially longer than in retail or food service categories. Investors should model a six-to-twelve month credentialing and ramp-up period as a baseline assumption. The current 4-unit franchise network with an investment range of $100,000 to $208,000 suggests a structure built for owner-operators with clinical backgrounds rather than passive investors seeking absentee income. Available territories and the FDD's territory exclusivity provisions should be confirmed directly with the franchisor. The FPI Score of 18, categorized as Limited, reflects the constrained data availability characteristic of a small franchise system with limited public disclosure history, and investors should weight this signal appropriately in their overall due diligence framework.

For the franchise investor conducting serious due diligence on the OPTION CARE franchise opportunity, the investment thesis rests on several converging factors that warrant careful, evidence-based evaluation. The home infusion market is projected to grow from $18.82 billion in 2023 to $33.2 billion by 2030, a market expansion of more than $14 billion that creates structural demand for qualified providers at every scale. The corporate parent's financial performance — $5.65 billion in 2025 revenue, $471 million in Adjusted EBITDA, and 2026 guidance reaching up to $6.0 billion — validates the underlying business model's commercial viability at scale. The 4-unit franchise network with a $100,000 to $208,000 initial investment range represents an accessible entry point relative to many healthcare franchise categories, though the absence of Item 19 financial disclosure means investors must construct independent unit economics projections. The FPI Score of 18 signals limited available performance data, which is a meaningful constraint on quantitative franchise evaluation and elevates the importance of direct FDD review, franchisee interviews, and independent market analysis. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data, and side-by-side comparison tools that allow investors to contextualize the OPTION CARE franchise opportunity against the full competitive landscape of home health care service franchise investments. The combination of a large and growing addressable market, a brand with a documented four-decade history in home infusion services, and an investment range that sits below many comparable healthcare franchise categories creates a profile that merits substantive investigation by the right candidate. Explore the complete OPTION CARE franchise profile on PeerSense to access the full suite of independent franchise intelligence data.